Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
07/11/2025
According to reports, the U.S. Treasury Department has sanctioned individuals who "exploited loopholes in currency exchange facilities in Lebanon to facilitate Iran's transfer of tens of millions of dollars to Hezbollah by 2025."
Latest
2 m ago
Eli Lilly (LLY.N): As part of an agreement with the Trump administration, it will receive a three-year tariff exemption.
2 m ago
According to White House sources, Lilly and Novo Nordisk will repatriate overseas revenue from their existing products and allow Medicaid programs in all states of the United States to benefit from most-favored-nation pricing.
3 m ago
Senior officials in the Trump administration: Eli Lilly and Novo Nordisk will lower the price of GLP-1 medications used to treat diabetes and other indications to $245 per month.
4 m ago
Lilly (LLY.US) and Novo Nordisk (NVO.US) both announced a straight line increase and reached an agreement with the US government to lower the price of GLP-1 while also obtaining a three-year tariff exemption. Senior officials of the Trump administration stated that approximately 10% of federal Medicare patients will be eligible to expand the use of GLP-1.
5 m ago
Senior officials of the Trump administration: Commercial health insurance companies will also be able to obtain GLP-1 medications at lower prices.
See all latest